• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence

byConstance Wu
April 21, 2021
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Polypill plus aspirin treatment was shown to decrease the incidence of cardiovascular events compared to placebo in patients without cardiovascular disease.

2. Adverse events such as hypotension and dizziness were shown to be higher in the polypill-only group compared to the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Polypills combining blood pressure (BP) and low-density lipoprotein (LDL) medications have been used to treat populations at risk for cardiovascular disease. The International Polycap Study 3 (TIPS-3) efficacy trial assessed whether treatment with a polypill alone, aspirin alone, or their combination would reduce the incidence of cardiovascular events among patients without cardiovascular disease. This randomized trial provides evidence that combination treatment with a polypill plus aspirin compared to placebo led to a lower incidence of cardiovascular events amongst participants with intermediate cardiovascular risk. Limitations pertinent to the trial include a lack of 5-year follow-up data, an underestimate of the true effect of treatment due to logistical obstacles, and an underestimation of the number of persons experiencing side effects. Nonetheless, the study’s results were significant as a polypill and aspirin treatment strategy reduced the incidence of cardiovascular events.

Click to read the study in NEJM

Relevant Reading: Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial

In-Depth [randomized controlled trial]: This randomized, controlled trial enrolled 5,713 participants at 86 centers in nine countries. Men 50 years of age or older and women 55 years of age with an INTERHEART Risk Score greater than or equal to 10 were included in the study. Patients with known cardiovascular disease were excluded from the study. Patients were randomized with a 2-by-2-by-2 factorial design into polypill (simvastatin 40 mg, atenolol 100 mg, hydrochlorothiazide 25 mg, ramipril 10 mg), aspirin (75 mg), and polypill plus aspirin, respectively. The primary outcome, with respect to the polypill and polypill plus aspirin groups, was death from cardiovascular causes, stroke, myocardial infarction, heart failure, resuscitated cardiac arrest, and arterial revascularization. The primary outcome, with respect to the aspirin group, was death from cardiovascular causes, myocardial infarction, or stroke. Overall, 126 participants (4.4%) in the polypill group experienced primary outcomes compared with 157 (5.5%) participants in the placebo group (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.63 to 1.00). Additionally, more participants in the polypill group compared to placebo stopped the trial regimen because of dizziness (polypill, 28 patients; placebo, 17 patients), hypotension (polypill,51 patients; placebo, 14 patients), or cough (polypill, 31 patients; placebo, 17 patients). Furthermore, 116 participants (4.1%) in the aspirin group compared to 134 participants (4.7) in the placebo group experienced primary outcomes (HR, 0.86; 95% CI, 0.67 to 1.10). Finally, 59 participants (4.1%) in the polypill plus aspirin group experienced primary outcomes compared to 83 participants (5.8%) in the double placebo group (HR, 0.69; 95% CI, 0.50 to 0.97). Overall, the polypill plus aspirin treatment resulted in a decrease in cardiovascular events incidence for patients without known cardiovascular disease.

RELATED REPORTS

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirincardiovascularheartheart attackMIpolypillstroke
Previous Post

ChAdOx1 nCoV-19 (AstraZeneca) vaccine is effective against the SARS-CoV-2 B.1.1.7 variant

Next Post

Percutaneous peripheral nerve stimulation effective for reduction of postoperative pain

RelatedReports

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Chronic Disease

CYP2C19 loss-of-function carriers have modest benefit from ticagrelor and aspirin following cerebrovascular event: CHANCE-2 Trial

June 23, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

June 13, 2022
Cardiology

Associations remain inconclusive between religiosity and spirituality on medication adherence in cardiovascular disease

May 16, 2022
Next Post

Percutaneous peripheral nerve stimulation effective for reduction of postoperative pain

Parental immunization status associated with likelihood of vaccinating children

AstraZeneca coronavirus vaccine rarely causes immune thrombotic thrombocytopenia

#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma

#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.